☆ 4.7 Review

An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy

CHEMICO-BIOLOGICAL INTERACTIONS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Materials Science, Biomaterials

Preparation and Evaluation of Gefitinib Containing Nanoliposomal Formulation for Lung Cancer Therapy

Seema Rohilla et al.

Summary: The present study developed and optimized nanoliposomes of gefitinib for effective tumor targeting. The nanoliposomes showed a small particle size, high entrapment efficiency, and sustained drug release, resulting in a significant cytotoxic response in cancer cells. These nanoliposomes also demonstrated good physical stability at low temperature and hold promise as a new anticancer formulation, although further clinical investigations are needed.

BIONANOSCIENCE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Impact of ecDNA: A mechanism that directs tumorigenesis in cancer drug Resistance-A review

Sumel Ashique et al.

Summary: Extrachromosomal DNA (ecDNA) is commonly found in cancer cells and plays a crucial role in cancer development and therapy resistance. It enhances gene transcription and resistance to chemotherapy, promotes tumor heterogeneity and phenotypic changes, leading to lower survival rates and chemotherapy tolerance.

CHEMICO-BIOLOGICAL INTERACTIONS (2022)

添加到收藏夹

Article Oncology

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Arlene Chan et al.

Summary: In early-stage breast cancer patients, neratinib provides a 5.1% increase in invasive disease-free survival and a 2.1% increase in overall survival at 8 years compared to placebo. For patients with residual disease after neoadjuvant therapy, the absolute benefits of neratinib are 7.4% and 9.1%, respectively.

CLINICAL BREAST CANCER (2021)

添加到收藏夹

Article Cell Biology

Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances

Zhi Chen et al.

Summary: The study found that the expression levels of ZNF436, beta-catenin, and EGFR were significantly higher in breast cancer tissues compared to paracancerous tissues, while CMTM5 was highly expressed in paracancerous tissues. The correlations of these indicators with the staging, differentiation, and lymphatic metastasis of breast cancer were also statistically significant. These findings suggest the potential of using ZNF436, beta-catenin, EGFR, and CMTM5 as molecular markers for breast cancer and provide a theoretical basis for targeted molecular therapies.

EUROPEAN JOURNAL OF HISTOCHEMISTRY (2021)

添加到收藏夹

Article Oncology

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Scott Kopetz et al.

Summary: Combination therapy of vemurafenib and irinotecan in patients with BRAF(V600E)-mutated colorectal cancer has shown improved progression-free survival, response rate, and disease control rate, as well as reduced BRAF(V600E) variant allele frequency in circulating tumor DNA.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Anti-inflammatory and anticancer activities of Naringenin-loaded liquid crystalline nanoparticles in vitro

Ridhima Wadhwa et al.

Summary: The study demonstrates that Naringenin-loaded liquid crystalline nanoparticles possess both anti-inflammatory and anticancer potential, reducing inflammatory markers and inhibiting lung cancer progression efficiently.

JOURNAL OF FOOD BIOCHEMISTRY (2021)

添加到收藏夹

Review Chemistry, Medicinal

Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy

Adileh Ayati et al.

Summary: Despite advancements in cancer treatment, EGFR inhibitors have shown significant improvement in targeted therapy. However, the emergence of epigenetic mutation and resistance issues have limited their effectiveness, leading to the need for further research in this field. Recent studies have focused on genetic alterations in the EGFR tyrosine kinase domain, resulting in the development of more selective and effective inhibitors.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Role of HGF/MET in liver cancer

Gaurav Gupta et al.

FUTURE MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma

Runping Fang et al.

Summary: In this study, it was revealed that YTHDF2 overexpression is associated with poor prognosis in glioma patients due to EGFR-induced protein stabilization, leading to reduced cholesterol homeostasis and promoting GBM tumorigenesis through an RNA m6A methylation dependent mechanism.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian et al.

Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.

NATURE (2021)

添加到收藏夹

Article Oncology

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Jacqueline V. Aredo et al.

Summary: Consolidation durvalumab did not benefit patients with EGFR-mutated unresectable stage III NSCLC and was associated with a high frequency of immune related adverse events. Patients who switched to osimertinib after durvalumab treatment may be more susceptible to incident adverse events. Further investigation is needed for concurrent CRT with induction or consolidation EGFR TKIs as definitive treatment.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Cell Biology

Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling

Xinya Gao et al.

Summary: The activation of EGFR signalling in GBM is driven by a newly discovered secretory E-cadherin protein variant called C-E-Cad encoded by circular RNA. This mechanism promotes tumorigenicity in glioma stem cells and provides a promising approach for treating EGFR-driven GBM by enhancing the efficacy of anti-EGFR strategies.

NATURE CELL BIOLOGY (2021)

添加到收藏夹

Article Oncology

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Gregory J. Riely et al.

Summary: Mobocertinib, an oral EGFR inhibitor targeting EGFR gene mutations in non-small cell lung cancer, demonstrated antitumor activity with manageable toxicity in patients with EGFRex20ins mutations in this study, supporting further development in this patient population.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling

Ai-lin Yang et al.

Summary: The study found that Cinobufagin inhibits the EGFR-CDK2 signaling pathway through multiple pathways, reducing the proliferation and colony formation capacity of human hepatoma cells. Additionally, Cinobufagin can decrease EGFR expression and CDK2 activity, demonstrating promising anticancer effects in HCC therapy.

TOXICOLOGY AND APPLIED PHARMACOLOGY (2021)

添加到收藏夹

Article Oncology

A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study

Huseyin Abali et al.

Summary: The study showed that trastuzumab in combination with chemotherapy and chemoradiotherapy as adjuvant therapy for gastric or gastroesophageal junction adenocarcinoma is safe and tolerable, with most patients able to complete the treatment plan successfully and exhibiting good survival rates.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)

添加到收藏夹

Review Cell Biology

Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned

Lorenzo Belluomini et al.

Summary: The current treatment landscape of early stage lung cancer is rapidly evolving, particularly in EGFR mutant NSCLC, where targeted therapy is moving to early stages. Limited data on the efficacy of neoadjuvant TKIs in EGFR mutant NSCLC have been reported, but the ADAURA trial has already proposed osimertinib as a potential new standard of care for resected NSCLC with activating EGFR mutations.

CELLS (2021)

添加到收藏夹

Article Oncology

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study

Zhi Peng et al.

Summary: The study reported the efficacy and safety of a novel anti-HER2 antibody RC48 in patients with HER2-overexpressing gastric cancer, showing promising therapeutic activity and manageable safety, suggesting potential application in patients who have previously received at least two lines of chemotherapy.

CANCER COMMUNICATIONS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Role of Glycosyltransferases in Colorectal Cancer

Cecilia Fernandez-Ponce et al.

Summary: The dysregulation of glycosyltransferase expression in colorectal cancer affects key molecules involved in oncogenesis and metastasis, impacting functions such as cell migration, cell-cell adhesion, apoptosis, and immune system regulation. Strategies to alter oligosaccharide processing and modify glycoconjugate structures have been evaluated to control CRC progression and prevent metastasis, while immunotherapy approaches target altered glycosylation as potential neo-antigens for tumor-specific T cells or engineered CAR T cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Oncology

Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)

Jingyi He et al.

Summary: Targeted therapy with EGFR-TKIs is standard for advanced EGFR-mutated NSCLC, with osimertinib being a representative 3rd-generation TKI for T790M-positive patients. However, complex resistance mechanisms including altered signaling pathways and cellular transformations challenge treatment efficacy, highlighting the need for novel combination therapies in addressing acquired resistance.

INTERNATIONAL JOURNAL OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park et al.

Summary: Amivantamab demonstrates robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations, even after progression on platinum-based chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Rutin loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro

Keshav Raj Paudel et al.

Summary: This study explored the anti-cancer activity of Rutin-loaded liquid crystalline nanoparticles (LCNs) in non-small cell lung cancer cell line, showing promising anti-proliferative and anti-migratory activities, induction of apoptosis, and inhibition of colony formation. These findings provide important insights for further mechanistic studies of Rutin-LCNs as a potential therapeutic option for NSCLC.

LIFE SCIENCES (2021)

添加到收藏夹

Letter Medicine, General & Internal

Osimertinib in EGFR-Mutated Lung Cancer

Wenhua Liang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

Denis M. Collins et al.

Summary: The study examined the impact of Tyrosine Kinase Inhibitors (TKIs) on HER2/EGFR expression levels and NK cell gene signatures, showing that TKIs may alter tumor cell phenotype and affect NK cell-mediated response to antibody therapies.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Cell Biology

Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy

Afshin Derakhshani et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2020)

添加到收藏夹

Review Oncology

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

Peter T. Harrison et al.

SEMINARS IN CANCER BIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

R. K. Murthy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Plant Sciences

beta-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway

Mingming Deng et al.

PHYTOMEDICINE (2020)

添加到收藏夹

Article Genetics & Heredity

Comprehensive pharmacogenomic characterization of gastric cancer

Jason K. Sa et al.

GENOME MEDICINE (2020)

添加到收藏夹

Review Oncology

HER2-positive advanced breast cancer treatment in 2020

Marcelle G. Cesca et al.

CANCER TREATMENT REVIEWS (2020)

添加到收藏夹

Article Oncology

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Vito Amodio et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors

Maria Vittoria Dieci et al.

CANCER TREATMENT REVIEWS (2020)

添加到收藏夹

Article Oncology

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial

Yu-Tao Liu et al.

CANCER MANAGEMENT AND RESEARCH (2020)

添加到收藏夹

Review Multidisciplinary Sciences

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer

Akira Inoue

PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2020)

添加到收藏夹

Article Nutrition & Dietetics

Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage

Hamid A. Bakshi et al.

NUTRIENTS (2020)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Systemic therapy for metastatic HER2-positive breast cancer

Philip Bredin et al.

SEMINARS IN ONCOLOGY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Antiproliferative effects of boswellic acids-loaded chitosan nanoparticles on human lung cancer cell line A549

Neeta Solanki et al.

FUTURE MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Oncology

ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer

Cletus A. Arciero et al.

CLINICAL BREAST CANCER (2019)

添加到收藏夹

Article Biology

Hydrogen bond analysis of the EGFR-ErbB3 heterodimer related to non-small cell lung cancer and drug resistance

Avirup Ghosh et al.

JOURNAL OF THEORETICAL BIOLOGY (2019)

添加到收藏夹

Article Cell Biology

MICAL-L2 potentiates Cdc42-dependent EGFR stability and promotes gastric cancer cell migration

Pengxiang Min et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)

添加到收藏夹

Article Oncology

The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer

Shahrzad S. Fard et al.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

PD-L1/PD-1 Axis in Glioblastoma Multiforme

Jakub Litak et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Current Approaches in NSCLC Targeting K-RAS and EGFR

Veronica Aran et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

The tumor-suppressive function of miR-1296-5p by targeting EGFR and CDK6 in gastric cancer

Yan Jia et al.

BIOSCIENCE REPORTS (2019)

添加到收藏夹

Review Oncology

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Funda Meric-Bernstam et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer

Jennifer W. Carlisle et al.

FUTURE ONCOLOGY (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

A Third Shot at EGFR: New Opportunities in Cancer Therapy

Salvador Guardiola et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer

Hyung Kwon Byeon et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2019)

添加到收藏夹

Article Toxicology

Mitogen-Activated Protein Kinase (MAPK): New Insights in Breast Cancer

Huanyu Lu et al.

JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY (2019)

添加到收藏夹

Review Oncology

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician

Vlad-Adrian Afrasanie et al.

RADIOLOGY AND ONCOLOGY (2019)

添加到收藏夹

Review Oncology

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

Eskil Eskilsson et al.

NEURO-ONCOLOGY (2018)

添加到收藏夹

Article Oncology

HER2-positive breast cancer: Current and new therapeutic strategies

Santiago Escriva-de-Romani et al.

BREAST (2018)

添加到收藏夹

Review Oncology

Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer

Renata Duchnowska et al.

CANCER TREATMENT REVIEWS (2018)

添加到收藏夹

Review Oncology

Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer

M. Cabanero et al.

CURRENT ONCOLOGY (2018)

添加到收藏夹

Article Oncology

HER2: An emerging target in colorectal cancer

Megan Greally et al.

CURRENT PROBLEMS IN CANCER (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

Zhenyi An et al.

ONCOGENE (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance

Stefano Fogli et al.

PHARMACOGENOMICS (2018)

添加到收藏夹

Review Oncology

Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

Joan Rou-En Choo et al.

TARGETED ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer

Ryan B. Corcoran et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Review Instruments & Instrumentation

Metastatic and triple-negative breast cancer: challenges and treatment options

Sumayah Al-Mahmood et al.

DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2018)

添加到收藏夹

Review Medicine, Research & Experimental

The role of pazopanib on tumour angiogenesis and in the management of cancers: A review

Dinesh Kumar Chellappan et al.

BIOMEDICINE & PHARMACOTHERAPY (2017)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.